SG10201806715TA - Use of inos inhibitors to increase viral yield in culture - Google Patents

Use of inos inhibitors to increase viral yield in culture

Info

Publication number
SG10201806715TA
SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA
Authority
SG
Singapore
Prior art keywords
culture
inos inhibitors
viral yield
increase viral
increase
Prior art date
Application number
SG10201806715TA
Other languages
English (en)
Inventor
Peter Pechan
Jeffery Ardinger
Abraham Scaria
Samuel Wadsworth
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201806715TA publication Critical patent/SG10201806715TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201806715TA 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture SG10201806715TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361750175P 2013-01-08 2013-01-08

Publications (1)

Publication Number Publication Date
SG10201806715TA true SG10201806715TA (en) 2018-09-27

Family

ID=51167323

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201806715TA SG10201806715TA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG10201913130PA SG10201913130PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG11201505333PA SG11201505333PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913130PA SG10201913130PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture
SG11201505333PA SG11201505333PA (en) 2013-01-08 2014-01-07 Use of inos inhibitors to increase viral yield in culture

Country Status (20)

Country Link
US (2) US11299715B2 (https=)
EP (3) EP2943567B1 (https=)
JP (2) JP6534933B2 (https=)
KR (1) KR102307279B1 (https=)
CN (1) CN105008523B (https=)
AR (1) AR094389A1 (https=)
AU (1) AU2014205604B2 (https=)
BR (2) BR112015016328B1 (https=)
CA (1) CA2897444A1 (https=)
DK (1) DK2943567T3 (https=)
ES (1) ES2651763T3 (https=)
HK (1) HK1249544A1 (https=)
HU (1) HUE037482T2 (https=)
IL (1) IL239824B (https=)
MX (2) MX360470B (https=)
NO (1) NO3050055T3 (https=)
RU (1) RU2676733C2 (https=)
SG (3) SG10201806715TA (https=)
TW (1) TWI608102B (https=)
WO (1) WO2014110053A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
PL3436593T3 (pl) 2016-03-28 2023-03-27 Ultragenyx Pharmaceutical Inc. Sposoby inaktywacji termicznej adenowirusów
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
ES3012649T3 (en) 2016-10-14 2025-04-09 Ultragenyx Pharmaceutical Inc Use of tonicifying agents to enhance recombinant adeno-associated virus yield
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Hdac阻害剤またはrepタンパク質を伴う細胞培養方法
JP7218303B2 (ja) 2017-05-09 2023-02-06 ウルトラジェニックス ファーマシューティカル インコーポレイテッド トランスフェクション試薬を生成するための拡大可能な方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
CN110835622B (zh) * 2018-08-16 2021-04-27 上海药明生物技术有限公司 用于调节哺乳动物细胞乳酸代谢的培养基及其应用
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
BR112022018658A2 (pt) 2020-03-16 2022-12-20 Ultragenyx Pharmaceutical Inc Métodos para potencializar o rendimento de vírus adenoassociado recombinante
WO2023157976A1 (ja) * 2022-02-21 2023-08-24 学校法人日本医科大学 ウイルスベクター生産性増強剤及びウイルスベクターの製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
RU2012335C1 (ru) * 1991-07-04 1994-05-15 Уфимский научно-исследовательский институт глазных болезней Ингибитор вируса простого герпеса
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
JP4044131B2 (ja) * 1992-07-31 2008-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ ヘルペスウイルスワクチン
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
US6833271B2 (en) 1996-12-04 2004-12-21 Medi-Cult A/S Serum-free cell culture media
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6783972B1 (en) * 1998-09-22 2004-08-31 University Of Florida Research Foundation Methods for large-scale production of recombinant AAV vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7091029B2 (en) * 2002-09-23 2006-08-15 Applied Genetics Technologies Corporation High titer recombinant AAV production
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
CN100348718C (zh) * 2005-10-18 2007-11-14 中国人民解放军军事医学科学院生物工程研究所 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基
CN101784532B (zh) * 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂

Also Published As

Publication number Publication date
EP2943567A1 (en) 2015-11-18
IL239824A0 (en) 2015-08-31
ES2651763T3 (es) 2018-01-29
RU2015133205A (ru) 2017-02-14
US20150353899A1 (en) 2015-12-10
CA2897444A1 (en) 2014-07-17
MX378877B (es) 2025-03-10
HK1214840A1 (en) 2016-08-05
KR102307279B1 (ko) 2021-09-29
EP3266866B1 (en) 2019-03-06
AU2014205604A1 (en) 2015-08-13
HUE037482T2 (hu) 2018-08-28
EP3521420A1 (en) 2019-08-07
BR112015016328B1 (pt) 2023-04-18
NO3050055T3 (https=) 2018-02-10
TWI608102B (zh) 2017-12-11
EP2943567B1 (en) 2017-09-13
JP6837094B2 (ja) 2021-03-03
RU2018144779A3 (https=) 2022-03-02
US11299715B2 (en) 2022-04-12
AU2014205604B2 (en) 2020-01-02
MX360470B (es) 2018-11-05
SG11201505333PA (en) 2015-08-28
DK2943567T3 (en) 2018-01-02
KR20150103275A (ko) 2015-09-09
BR112015016328A2 (https=) 2017-09-05
US20220340883A1 (en) 2022-10-27
JP2019187420A (ja) 2019-10-31
MX2015008861A (es) 2016-04-13
HK1249544A1 (en) 2018-11-02
RU2676733C2 (ru) 2019-01-10
SG10201913130PA (en) 2020-03-30
AR094389A1 (es) 2015-07-29
CN105008523A (zh) 2015-10-28
RU2018144779A (ru) 2019-01-29
WO2014110053A1 (en) 2014-07-17
CN105008523B (zh) 2020-03-27
IL239824B (en) 2019-03-31
EP3266866A1 (en) 2018-01-10
JP2016504913A (ja) 2016-02-18
TW201446965A (zh) 2014-12-16
JP6534933B2 (ja) 2019-06-26
BR122020002822B1 (pt) 2023-04-18

Similar Documents

Publication Publication Date Title
SG10201806715TA (en) Use of inos inhibitors to increase viral yield in culture
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
MX2015009037A (es) Enjuague nasal con miel.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX379251B (es) Producción mejorada de derivados de ácidos grasos.
EP2808318A4 (en) CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF
EP2803657A4 (en) CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF
MX2015014816A (es) Compuestos de microarn y metodos para modular al mir-122.
UA113620C2 (xx) Композиція, що містить аморфну (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)оцтову кислоту
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
IN2014DN07958A (https=)
AU2016204276A1 (en) Methods for producing virus particles with simplified glycosylation of surface proteins
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MD20130073A2 (en) New crystal form VII of agomelatine, preparation method and use thereof, and pharmaceutical composition containing the same
IN2013MU01431A (https=)
MY170453A (en) Etching material
EP3242932A4 (en) Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
MX2020002286A (es) Composicion para el tratamiento del cancer asociado con la infeccion del hpv.
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
WO2015066488A3 (en) Method for producing induced pluripotent stem cells
IN2014DN10683A (https=)
MX353587B (es) Formulaciones farmacéuticas que contienen ipidacrina y su uso para el tratamiento de trastornos de potencia y trastornos de otras formas de actividad sexual.